Jul 05, 2012 - Radiation Countermeasure

Acute Radiation Syndrome (ARS) is an area of high unmet need, as there are no current FDA approved therapies. The unique mechanism of action of TPO-7630 increases the cells’ ability to deal with radiation-induced oxidative cell damage, promoting its survival. TPO-7630 is being developed as a therapeutic to be given before (prophylactic) or after (mitigator) radiation exposure to treat civilians, military personnel, and first responders.

Additional RLIP76 protein protects the cell from radiation exposure.




means therapy in Esperanto, an international, constructed language introduced by Dr. L.L. Zamenhof in 1887.